secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001558370-23-001572
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences Q4 2022 net revenue $128.3M (+41% YoY); full-year net income $181.5M
--------------------------------------------------------------------------------

- Q4 net product revenue $128.3M, up 41% YoY; average patients on WAKIX ~4,900.
- GAAP net income Q4 $48.5M ($0.79 diluted EPS); non-GAAP adjusted $61.9M ($1.01).
- Full year 2022 net revenue $437.9M (+43% YoY); net income $181.5M.
- Phase 3 idiopathic hypersomnia INTUNE study continues with strong momentum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023001572/0001558370-23-001572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023001572/hrmy-20230221x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-001572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer